SoftServe Achieves VMware Master Services Competency in VMware Cloud on AWS
11.2.2021 15:00:00 EET | Business Wire | Press release
SoftServe, a leading digital authority and consulting company, today announced that it has successfully achieved the VMware Cloud on AWS VMware Master Services Competency. This competency demonstrates that SoftServe is committed to helping organizations accelerate their digital transformations by leveraging their validated services delivery capabilities around advanced VMware technologies.
“As a VMware Principal Partner, SoftServe has advanced technical proficiency, delivery expertise, and proven customer success in deploying hybrid cloud solutions using VMware Cloud on AWS,” said Todd Lenox, Vice President, Global Alliances and Partnerships at SoftServe. “Our ability to provide customers with a smooth and seamless transition to the Cloud allows them to run applications across a VMware Cloud Infrastructure environment with access to a broad range of AWS services.”
“VMware is pleased to recognize SoftServe for achieving the VMware Cloud on AWS Master Services Competency. This achievement shows customers that partners like SoftServe are invested, dedicated, and have validated expertise in advanced VMware technologies,” said Sandy Hogan, SVP of Worldwide Commercial and Partner Sales, VMware. “We value SoftServe as a VMware partner, and appreciate their efforts in achieving this VMware distinction.”
VMware Master Services Competencies are designed to help partners demonstrate customer-centric solutions and technical proficiency, with proven success and expertise in a specialized area of business. These competencies also allow partners to differentiate in five specific solution areas.
VMware partners can achieve VMware Master Services Competencies in:
- Cloud Management and Automation – Designates expertise in delivery of VMware Cloud Management and Automation solutions and services with deep understanding and execution of cloud management design principles and methodologies.
- Data Center Virtualization – Designates expertise in delivery of VMware vSphere environments and digital infrastructure services with deep understanding of and execution in Data Center Virtualization design principles and methodologies.
- Desktop and Mobility – Designates expertise in designing, installing, and maintaining VMware Workspace ONE and VMware Horizon solutions with deep understanding of and execution in desktop and mobility design principles and methodologies to deliver a scalable and reliable digital workspace.
- Network Virtualization – Designates expertise in the delivery of VMware NSX environments and services with deployment and optimization of NSX environment capabilities.
- VMware Cloud on AWS – Designates expertise in the delivery of hybrid cloud solutions based on VMware Cloud on AWS. This service provides an operationally consistent and familiar way to run, manage and secure applications in a hybrid IT environment.
The VMware Partner Connect program empowers partners with the flexibility to meet customers’ needs, making VMware technologies and services more accessible. Partners have an enhanced experience that delivers simplicity, choice and innovation, and recognizes and rewards partners based on the value they bring to customers.
SoftServe implements VMware-powered solutions by leveraging its expertise in cloud adoption, DevOps, and end-to-end app modernization services. With advanced software development and automation success, SoftServe facilitates reduced development cycle times and deployment costs while delivering speed, agility, and greater efficiency at scale.
For more information, please visit SoftServe’s VMware partner page.
About SoftServe
SoftServe is a digital authority that advises and provides at the cutting-edge of technology. We reveal, transform, accelerate, and optimize the way enterprises and software companies do business. With expertise across healthcare, retail, energy, financial services, software, and more, we implement end-to-end solutions to deliver the innovation, quality, and speed that our clients’ users expect.
SoftServe delivers open innovation—from generating compelling new ideas, to developing and implementing transformational products and services. Our work and client experience is built on a foundation of empathetic, human-focused experience design that ensures continuity from concept to release. We empower enterprises and software companies to (re)identify differentiation, accelerate solution development, and vigorously compete in today’s digital economy. No matter where you are in your journey.
Visit our website, blog, LinkedIn, Facebook, and Twitter pages.
VMware, vSphere, Workspace ONE, Horizon, and NSX are registered trademarks or trademarks of VMware, Inc. in the United States and other jurisdictions. All other marks and names mentioned herein may be trademarks of their respective companies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005012/en/
Contact information
Paul Jones
Senior Manager, Analyst and Public Relations
pjone@softserveinc.com
512-796-7358
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom